Search the Newsreel

H.C. Wainwright reiterates Aligos stock rating on HBV progress

H.C. Wainwright reaffirmed a Buy rating and $50 price target for Aligos Therapeutics Inc. (NASDAQ:ALGS) following positive updates on its chronic hepatitis B virus infection treatments, including breakthrough therapy designation for pevifoscorvir sodium in China and complete enrollment of the Phase 2 B-SUPREME trial. …

Lake Street Keeps Their Buy Rating on Aligos Therapeutics (ALGS)

Is Goldman Sachs Group (GS) Still Below Fair Value On Its New Senior Notes?

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Goldman Sachs event and why it matters for stock watchers Goldman Sachs Group (GS) has launched a fresh series of callable senior notes …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Gossamer Bio, Inc. (GOSS) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gossamer Bio, Inc. (NASDAQ: GOSS) securities. The investigation focuses on whether Gossamer and its officers engaged in corporate wrongdoing. The firm encourages investors who bought Gossamer shares before June 16, …

Lake Street Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $45

Lake Street has reiterated its Buy rating on Aligos Therapeutics (ALGS.US) and maintained its target price at $45. This suggests continued confidence in the company's financial prospects and growth potential from the analyst firm.

Goldman Sachs Group Inc (GS) Aktuelle Aktien-News

Gossamer Bio Inc (GOSS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Gossamer Bio Inc (GOSS) has an earnings forecast score of 6.50, ranking 325 out of 387 in its industry, with an average price target of $9.00 based on 8 analysts. The market expects the company's revenue for the next quarter to be $5.19M and …

Is The Goldman Sachs Group (GS) Outperforming Other Finance Stocks This Year?

Investors interested in Finance stocks should always be looking to find the best-performing companies in the group. Goldman Sachs (GS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a …

Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

Aligos Therapeutics, Inc. has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters, provides a brief update on the company's financial performance. Readers are encouraged to access the full report on TradingView for complete details.

Goldman Skeptical of Dollar-Dominance Threats After Yen Support

(Bloomberg) -- US support for Japan's efforts to prop up the yen is unlikely to damage the dollar's status as the most dominant reserve currency in the world, according to Goldman Sachs Group Inc. Most Read from Bloomberg Iran Says Agreement on Hormuz Shipping …

Aligos Therapeutics 2Q 2026: Revenue $—, Net income $(1.50)M, EPS $(0.14) — 10-Q Summary

Aligos Therapeutics reported its second-quarter 2026 results, showing a net loss of $(1.50)M and diluted EPS of $(0.14), which is a narrower loss compared to the previous year. The company's revenue momentum was driven by $27.8M in license revenue, primarily from an exclusive Greater …

Form 8K Aligos Therapeutics Inc For: 6 August By Investing.com

This article reports on an SEC Form 8K filing by Aligos Therapeutics Inc. on August 6th. The filing indicates a significant event or change for the company, as reflected by its stock symbol ALGS, which showed a 16.24% increase.

Aligos Therapeutics reports Q2 2026: $27.8M licensing revenue, $1.5M net loss, $30.4M cash

Aligos Therapeutics announced its Q2 2026 financial results, reporting $27.8 million in licensing revenue and a net loss of $1.5 million. The company ended the quarter with $30.4 million in cash, excluding a $25 million upfront payment received in July 2026. Key business developments …

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

Aligos Therapeutics reported significant business progress and financial results for Q2 2026, highlighting advances in its liver and viral disease pipeline. Key achievements include the completion of enrollment for the Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic HBV, its Breakthrough Therapy Designation …

ALIGOS THERAPEUTICS Q2 NET INCOME USD -1.504 MILLION

ALIGOS THERAPEUTICS reported a net income of USD -1.504 million for the second quarter. This financial update provides a key insight into the company's recent performance.

Aligos Therapeutics (Nasdaq: ALGS) logs Q2 loss but lands $27.8M HBV license revenue

Goldman Sachs stock doubles from 'Liberation Day' lows

Goldman Sachs (GS) stock fell by roughly 9% on April 3, 2025, closing at $511.02 the day after President Trump's "Liberation Day" announcement. A year and a quarter later, the bulge-bracket bank's stock has doubled, closing at $1,052.98 on Tuesday, an appreciation of roughly …

Rightmove (LSE:RMV) Stock Gets Fair Value Trim As Analysts Weigh Growth And Execution

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. The latest research on Rightmove centres on a revised price target that has moved from 404 GBp to 429 GBp. Analysts link this …

The Zacks Analyst Blog Highlights Comfort Systems, The Goldman Sachs, Vertiv, Seagate and The Travelers

For Immediate Release Chicago, IL – August 5, 2026 – Zacks.com announces the list of stocks and ETFs featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently …

Talcott Financial Group Launches West Grove Re in Partnership with Goldman Sachs

Newly formed Bermuda-domiciled reinsurance vehicle to accelerate Talcott's growth strategy by providing additional access to third-party capital HARTFORD, Conn., August 04, 2026--(BUSINESS WIRE)--Talcott Financial Group ("Talcott"), an international life insurance group providing comprehensive risk solutions for customers across the retirement and insurance industry, today …

Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Gossamer Bio, Inc. (NASDAQ:GOSS) on behalf of investors who purchased securities prior to June 16, 2025, and still hold them. The investigation focuses on whether Gossamer's officers and/or directors engaged in corporate wrongdoing. The …

Werden die Anleiheemissionen und Premium-ETFs von Goldman Sachs (GS) das zentrale Anlage-Narrativ des Unternehmens verändern?

Goldman Sachs (GS): Buy, Sell, or Hold Post Q2 Earnings?

Goldman Sachs trades at $1,016 and has moved in lockstep with the market. Its shares have returned 8.2% over the last six months while the S&P 500 has gained 8.3%. Is now the time to buy Goldman Sachs, or should you be careful about …

Anthony Scaramucci Says His 'Fully Flammable' $90 Polyester Suit Almost Sank His Goldman Sachs Career Before It Started: 'I Thought I Looked Fantastic...'

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. SkyBridge Capital founder Anthony Scaramucci reflected on his working-class upbringing and an awkward first interview at Goldman Sachs, using the experience to encourage young people pursuing opportunities …

Big Tech is seeing a 'valuation pullback,' Goldman Sachs shows

Yahoo Finance Senior Reporter Brooke DiPalma takes a closer look at Goldman Sachs's (GS) note about Big Tech devaluation and market broadening. Video Transcript 00:00 Speaker A Brooke, I know you were digging into that Goldman Sachs note I mentioned uh from Peter Oppenheimer …

gossamer bio inc. Earnings dates

This article provides the upcoming earnings dates for Gossamer Bio Inc. (GOSS), including estimates for Q3 2024 and Q4 2025. It also lists recent news headlines related to Gossamer Bio, covering topics such as FDA filings, clinical trial results, and acquisitions.

Where Does Oil Go Next After the Hormuz Crisis?

Samantha Dart, Co-Head of Global Commodities Research at Goldman Sachs, discusses how oil prices may develop if the conflict in the Strait of Hormuz continues to escalate, and warns that a supply glut may pose a challenge even if the supply interruptions are resolved. …

BlackRock (GOSS) discloses 4.89M-share, 1% beneficial stake in Gossamer Bio

BlackRock, Inc. has filed an amended ownership report disclosing a beneficial stake of 4,890,593 shares, representing 1.0% of Gossamer Bio, Inc.'s common stock, as of June 30, 2026. BlackRock holds sole voting and sole dispositive power over these shares. This filing, a Schedule 13G/A, …

Goldman Sachs Stock Rises 3.2% as AlphaAI Platform Launches

This article first appeared on GuruFocus. Goldman Sachs (NYSE:GS), a global investment bank and asset-management company, rose approximately 3.2% in Thursday's regular-session trading as investors assessed the launch of its AlphaAI investment platform. Goldman Sachs Asset Management created the platform to use artificial intelligence …

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

Aligos Therapeutics (NASDAQ: ALGS), a clinical-stage biotechnology company focusing on liver and viral diseases, announced it will release its second quarter 2026 financial results on Thursday, August 6, 2026, before U.S. financial markets open. The company's stock rose 5.4% following this announcement, consistent with …

Market Chatter: Goldman Sachs Ordered to pay Former Compliance Manager $2 Million in UK Discrimination case

Goldman Sachs (GS) has been ordered to pay nearly 1.5 million pounds ($2 million) to a former compli PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. …

Should Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) Be on Your Investing Radar?

The Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) was launched on September 12, 2017, and is a passively managed exchange traded fund designed to offer broad exposure to the Large Cap Blend segment of the US equity market. The fund is …

Aligos Therapeutics Inc (ALGS) Valuation: PE, PB & Fair Value Analysis

Aligos Therapeutics Inc (ALGS) has a current valuation score of 8.75, placing it 62nd out of 385 companies in the Biotechnology & Medical Research industry. Its P/E ratio is -0.43, indicating it is -31.58% below its recent high and significantly above its recent low. …

Aligos Therapeutics to report results before markets open Aug. 6

Aligos Therapeutics Inc (ALGS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Aligos Therapeutics Inc (ALGS), focusing on current price momentum, support and resistance levels, and various technical indicators and moving averages. The stock currently has a price momentum score of 5.70, trading between a resistance of 6.23 and …

Goldman Says Diesel at ‘Epicenter’ of Squeeze as Refineries Hit

(Bloomberg) -- Diesel is "at the epicenter" of a supply squeeze in fuels as global refinery activity fell this month to its lowest seasonal level since the pandemic, according to Goldman Sachs Group Inc. Most Read from Bloomberg Stocks Fall as 30-Year Bond Yields …